Guardant Health Earnings Call Highlights Breakout Growth

Guardant Health ((GH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Guardant Health’s latest earnings call struck an upbeat tone as management highlighted a breakout quarter across oncology, biopharma and screening. Revenue growth accelerated, margins improved and new AI, data and partnership initiatives pointed to multi‑year upside, even as executives acknowledged rising expenses, persistent losses and reimbursement risks that could test execution.

Strong Top-Line Revenue Growth and Raised Guidance

Guardant reported Q1 revenue of $302 million, up 48% year over year, pushing trailing 12‑month revenue above the $1 billion mark. Management’s confidence led them to lift 2026 revenue guidance to $1.30–$1.32 billion, implying growth of 32%–34% and signaling continued demand across the portfolio.

Oncology Momentum — Volume and Revenue Expansion

Oncology remained the core growth engine, with revenue reaching $205 million, up 36% from a year ago and test volumes climbing 47% to about 86,000. Flagship Guardant360 Liquid grew 30%, tissue testing became the second‑fastest grower and Reveal volumes more than doubled, supporting outlooks for oncology revenue growth of 28%–29% and volume expansion above 35% in 2026.

Breakout Screening (Shield) Performance

Screening product Shield delivered a standout quarter, with revenue jumping to $42 million from just $6 million in the prior year and test volumes rising to roughly 44,000 from about 9,000. Momentum accelerated in March after a nationwide Quest launch and aggressive direct‑to‑consumer and physician campaigns, prompting management to raise 2026 Shield revenue guidance to $186–$198 million on 230,000–245,000 tests.

Material Improvement in Screening Economics

Screening economics improved sharply as non‑GAAP gross margin rose from 18% to 56% year over year, driven by better scale and lower Shield costs. Shield’s non‑GAAP cost per test fell from $520 to $420 while a Medicare fee‑for‑service rate of $1,495 was set, and management reiterated a path to roughly $200 per‑test cost at scale targeted for 2027.

Biopharma & Data Growth and Strategic Partnerships

Biopharma & Data revenue reached $53 million, up 17% year over year, supported by an expanding companion diagnostics footprint that now includes 26 approvals across key global markets. New multiyear deals with major pharma partners and collaborations such as with Nuvalent, plus InfinityAI‑driven real‑world evidence enabling a tumor‑agnostic approval in Japan, underline the strategic value of Guardant’s data assets.

Improved Margins Driven by Sequencing Cost Reduction

Company‑wide non‑GAAP gross margin ticked up to 66% from 65% as a transition to NovaSeq X technology cut Guardant360 Liquid sequencing costs by nearly $200 per test versus last year. Management guided full‑year non‑GAAP gross margin to 64%–65%, suggesting continued leverage even as screening volumes scale and mix evolves.

Data Treasury and AI Platform Progress

Guardant highlighted a growing data repository now exceeding 1 million patient samples and 500,000 epigenetic profiles across more than 100 tumor types, forming a core competitive moat. Its InfinityAI platform powered 25 of 38 AACR abstracts and multiple Smart Apps, with additional applications and Reveal submissions progressing through MolDx pathways to unlock further clinical and commercial value.

Operational Strength and Cash Position

Operationally, adjusted EBITDA loss held at $59 million year over year, while free cash flow burn was $71 million versus $67 million despite higher bonuses, implying an underlying $12 million improvement. The company ended the quarter with about $1.2 billion in cash and investments and reaffirmed plans to reduce 2026 free cash flow burn and reach company‑wide cash‑flow breakeven by the end of 2027.

Commercial and Patient Engagement Catalysts

Commercial reach expanded as the nationwide Quest partnership went live and electronic medical record connectivity was fast‑tracked to more than 650,000 healthcare providers, smoothing ordering and adoption. A high‑profile ad campaign, including a Patrick Dempsey‑fronted push, generated over a billion impressions, while Shield adherence exceeded 90% and an FDA‑approved reduction from four to two blood tubes improved the patient experience.

Increased Operating Expense Base

The growth push came with a cost as non‑GAAP operating expenses climbed 34% to $268 million, driven mainly by sales and marketing spend rising to $154 million from $94 million to support screening scale‑up. Full‑year non‑GAAP operating expenses are now guided to $1.05–$1.07 billion, up 16%–18% year over year, with management explicitly reinvesting incremental Shield gross profit into further expansion.

Ongoing Adjusted Losses and Cash Burn

Despite margin gains, Guardant remains in loss‑making territory, with adjusted EBITDA still negative $59 million in the quarter and the business not yet cash‑flow positive. For 2026, the company expects free cash flow burn of $185–$195 million, an improvement versus the prior year but still a meaningful outflow that investors will watch closely as the growth strategy plays out.

Reimbursement and Regulatory Uncertainties

Management acknowledged that several upside levers hinge on external reimbursement and regulatory decisions, including MolDx reviews tied to Reveal’s use in breast minimal residual disease and treatment monitoring. Broader commercial payer coverage and guideline inclusion for Shield remain pending, creating uncertainty around how quickly adoption in patients under 65 can translate into sustained revenue.

Dependence on External Drug Approvals for Upside

Certain Guardant360 Liquid monitoring use cases, such as ESR1 tracking, rely on approvals of specific therapies, which adds another layer of dependency outside the company’s control. The recent negative advisory vote on a key drug candidate highlighted this risk, and management underscored that current guidance does not assume approval, tempering expectations for near‑term upside from this avenue.

Mix-Related ASP Pressure as Patient Mix Shifts

Shield’s average selling price in Q1 benefited from a Medicare‑heavy mix, providing a near‑term boost to revenue metrics that may not persist as volumes broaden. Management signaled that as more patients under 65 are tested and commercial coverage lags, average Shield ASPs could moderate toward roughly $775 in the remaining quarters, putting some pressure on revenue per test even as volumes scale.

Competitive and Execution Risks

Guardant operates in an increasingly competitive landscape with larger diagnostics players ramping up their own access and commercial infrastructure, intensifying the fight for market share and sales talent. Management indicated that balancing organic growth with potential deals, while executing on multiple product and AI initiatives, will be critical to sustaining momentum against well‑capitalized rivals.

Forward-Looking Guidance and Strategic Outlook

Looking ahead, Guardant’s raised 2026 outlook calls for robust double‑digit growth across oncology, biopharma and screening, underpinned by expanding Shield volumes and improving gross margins. Management expects the core business excluding screening to be free‑cash‑flow positive and is targeting company‑wide cash‑flow breakeven by 2027, while potential FDA approvals and continued cost reductions toward roughly $200 per Shield test provide additional optionality.

Guardant’s earnings call painted the picture of a company in high‑growth investment mode, pairing strong top‑line momentum and improving unit economics with a still‑sizable cash burn. For investors, the story hinges on whether the company can translate its data assets, AI platform and commercial partnerships into durable profitability while navigating reimbursement, regulatory and competitive challenges over the next few years.